The stocks of companies that make or are developing the new class of weight-loss and diabetes-management drugs were sharply ...

The chart below compares the forward price to earnings (P/E) ratio of AstraZeneca to multiples in a peer set of leading ...

Should you forget Eli Lilly and buy this magnificent biotech instead? Let's find out.

Novo Nordisk said Monday it has launched its popular obesity drug Wegovy in China, the world’s second-largest pharmaceuticals market where it estimates more than 180 million people live with obesity.

Lower Manhattan-based Metsera is one of the latest drug startups to throw its hat into the ring with the pharma giants ...